The Use of Busulphan As Compared to Melphalan in Combination with Fludarabine in the Reduced Intensity Conditioning Improves Overall Survival in Patients with Lymphoma

被引：0
|
作者：
Kekre, Natasha [1 ]
Marquez-Malaver, Francisco J. [2 ]
Caballero, Dolores [3 ]
Pinana, J. I. [4 ]
Esquirol, Albert [5 ]
Soiffer, Robert J. [6 ]
Cabrero, Monica [7 ]
Terol, M. J. [4 ]
Martino, Rodrigo [8 ]
Antin, Joseph H. [9 ]
Lopez Corral, L. [7 ]
Solano, Carlos [10 ]
Armand, Philippe [1 ]
Perez-Simon, Jose A. [11 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Seville, CSIC, Hosp Univ Virgen Rocio, Dept Hematol,Inst Biomed Sevilla IBIS, Seville, Spain
[3] Hosp Univ Salamanca, Salamanca, Spain
[4] Hosp Clin Univ, Dept Hematol Oncol, Valencia, Spain
[5] Hosp Santa Creu & Sant Pau, Jose Carreras Leukemia Res Inst, Clin Hematol Serv, Barcelona, Spain
[6] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[7] Univ Salamanca, Inst Biosanitario Salamanca IBSAL, Univ Hosp, Hematol Serv, E-37008 Salamanca, Spain
[8] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[9] Childrens Hosp, Dana Farber Canc Inst, Massachusetts Gen, Boston, MA 02115 USA
[10] Hosp Clin Univ La Fe, Dept Hematol, Valencia, Spain
[11] Hosp Univ Virgen del Rocio, Dept Hematol, Seville, Spain
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Fludarabine plus high dose melphalan or busulphan are reduced intensity but truly myeloablative conditioning regimens
    Pardo Gonzalez, C.
    Gonzalez, A.
    Fernandez, R.
    Gonzalez, A.
    Palomo, P.
    Gonzalez, S.
    Arija, E.
    Martinez-Mugica, C.
    Rayon, C.
    Vallejo, C.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S237 - S238
  • [2] Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma
    Kekre, Natasha
    Marquez-Malaver, Francisco J.
    Cabrero, Monica
    Pinana, Jl
    Esquirol, Albert
    Soiffer, Robert J.
    Caballero, Dolores
    Terol, M. J.
    Martino, Rodrigo
    Antin, Joseph H.
    Lopez-Corral, L.
    Solano, Carlos
    Armand, Philippe
    Perez-Simon, Jose A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (10) : 1808 - 1815
  • [3] Fludarabine and Melphalan Results in Fewer Relapses Compared to Fludarabine and Targeted Busulfan in Patients Receiving Reduced Intensity Conditioning for AML and MDS
    Caddell, Ryan James
    Schaible, Braydon
    Ma, Zhenjun
    Dimaggio, Elizabeth
    Tombleson, Rebecca
    Anasetti, Claudio
    Ayala, Ernesto
    Betts, Brian C.
    Kharfan-Dabaja, Mohamed A.
    Locke, Frederick L.
    Nishihori, Taiga
    Pidala, Joseph A.
    Fernandez, Hugo F.
    Mishra, Asmita
    BLOOD, 2016, 128 (22)
  • [4] Clonal gammopathies following reduced intensity conditioning transplantation with fludarabine, busulphan and alemtuzumab for myeloid malignancies predict improved overall survival.
    Lim, ZY
    Pagliuca, A
    Ingram, W
    Milojkovic, D
    Akthari, M
    Ho, A
    Devereux, S
    Duarte, R
    Mufti, GJ
    BLOOD, 2005, 106 (11) : 407A - 407A
  • [5] Comparison of Reduced-Intensity Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Patients 50 Years or Older
    Kawamura, Koji
    Kako, Shinichi
    Mizuta, Shuichi
    Ishiyama, Ken
    Aoki, Jun
    Yano, Shingo
    Fukuda, Takahiro
    Uchida, Naoyuki
    Ozawa, Yukiyasu
    Eto, Tetsuya
    Iwato, Koji
    Ichinohe, Tatsuo
    Atsuta, Yoshiko
    Kanda, Yoshinobu
    BLOOD, 2016, 128 (22)
  • [6] Fludarabine Busulfan Compared to Fludarabine Melphalan Is Associated with Increased Relapse Risk in Reduced Intensity Conditioning Transplant Despite Pharmacokinetic Dosing
    Damlaj, Moussab
    Alkhateeb, Hassan B.
    Partain, Daniel K.
    Almasri, Jehad
    Hefazi, Mehrdad
    Hashmi, Shahrukh K.
    Gastineau, Dennis A.
    Al-Kali, Aref
    Wolf, Robert C.
    Gangat, Naseema
    Litzow, Mark R.
    Hogan, William J.
    Patnaik, Mrinal M.
    BLOOD, 2015, 126 (23)
  • [7] Immune Reconstitution after Alemtuzumab, Fludarabine, and Melphalan Reduced Intensity Conditioning
    Daniels, Pauline A.
    Bleesing, Jack
    Chandra, Sharat
    Dandoy, Christopher E.
    Davies, Stella M.
    El-Bietar, Javier
    Grimley, Michael S.
    Jodele, Sonata
    Jordan, Michael B.
    Khandelwal, Pooja
    Kumar, Ashish
    Mehta, Parinda A.
    Myers, Kasiani C.
    Nelson, Adam S.
    Marsh, Rebecca A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (03) : S163 - S164
  • [8] Relationship of iothalamate clearance and NRM in patients receiving fludarabine and melphalan reduced-intensity conditioning
    Kutzke, Jade L.
    Merten, Julianna A.
    Pawlenty, Amanda G.
    Barreto, Erin F.
    Bartoo, Gabe T.
    Mara, Kristin C.
    Litzow, Mark R.
    Hogan, William J.
    V. Shah, Mithun
    Mangaonkar, Abhishek A.
    Leung, Nelson
    Alkhateeb, Hassan B.
    BLOOD ADVANCES, 2022, 6 (13) : 3844 - 3849
  • [9] Oral fludarabine is an effective and convenient alternative to intravenous fludarabine in fludarabine melphalan based reduced intensity conditioning regimens
    Y. Lwin
    J. Lindsay
    C. Reid
    K. Wong
    I. Kerridge
    C. Arthur
    K. Fay
    W. Stevenson
    M. Greenwood
    Bone Marrow Transplantation, 2020, 55 : 1638 - 1641
  • [10] Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma
    Majolino, Ignazio
    Davoli, Marina
    Carnevalli, Ellen
    Locasciulli, Anna
    Di Bartolomeo, Paolo
    Scime, Rosanna
    Corradini, Paolo
    Selleri, Carmine
    Narni, Franco
    Musso, Maurizio
    Bregni, Marco
    Olivieri, Attilio
    De Fabritiis, Paolo
    Pogliani, Luigi
    Arbelaez, Jorge E. Duque
    Ruscio, Carla
    Bacigalupo, Andrea
    LEUKEMIA & LYMPHOMA, 2007, 48 (04) : 759 - 766
12345